<?xml version="1.0" encoding="UTF-8"?>
<p>As a part of cell-based screening of 725 FDA-approved drugs, Lovastatin, an HMG-CoA reductase inhibitor was tested against ZIKV and found to be potent through a dose–response assay (EC50 = 20.7 _ 8.6 mM) [
 <xref rid="B96-pharmaceuticals-12-00157" ref-type="bibr">96</xref>]. Another related drug, Mevastatin also showed anti-ZIKV activity at concentrations of 1–5 mM, but found not to be dose-responsive above 5 mM [
 <xref rid="B112-pharmaceuticals-12-00157" ref-type="bibr">112</xref>]. Since Mevastatin is known to induce apoptosis [
 <xref rid="B134-pharmaceuticals-12-00157" ref-type="bibr">134</xref>], perhaps it showed lack of antiviral activity at higher concentrations.
</p>
